Education
About Us
Working with TipRanks
Follow Us
Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $4.32
Previous CloseN/A
Volume307.14K
Average Volume (3M)8.04M
Market Cap
$14.59M
Enterprise Value-$1.81M
Total Cash (Recent Filing)$5.42M
Total Debt (Recent Filing)$24.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 17, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding9,119,152
10 Day Avg. Volume21,939,831
30 Day Avg. Volume8,036,851
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-453.61
Enterprise Value/Gross Profit1.81K
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$2.00Price Target Upside25.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPalisade announced additional highly positive data from the Phase 1b trial of PALI-2108, showing 100% clinical response in ulcerative colitis patients.
Market OpportunityPalisade Bio is focusing on developing PALI-2108 for fibrostenotic Crohn’s disease, where there are currently no FDA approved therapies, making it a targetable market with less competition.
Safety And TolerabilityPALI-2108 was found to be well-tolerated with no serious adverse events, suggesting safety alongside its effectiveness.
Bears Say
Regulatory ChallengesPalisade plans to initiate a Phase 1b to better evaluate PALI-2108 for fibrostenotic Crohn’s disease, meet with the FDA, and file an IND for an eventual Phase 2 study.
Trial LimitationsThe data, while from a small n-value, is overall directionally positive, supporting the hypothesis that PALI-2108 selectively engages the colon while generating a biologic effect on patients and reducing associated symptoms.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $4.32 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $14.59M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Nov 17, 2025 which is in 42 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 19, 2025. The company reported -$0.581 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $0.013.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.38.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 9,119,152 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -$0.581 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
Company Description
Palisade Bio
Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.
PALI Stock 12 Month Forecast
Average Price Target
$2.00
▲(25.00% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Quoin Pharmaceuticals
―
Artelo Biosciences
―
Galecto
―
SciSparc Ltd.
―
Ownership Overview
0.24% Insiders
0.32% Mutual Funds
0.30% Other Institutional Investors
99.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---